Day 3: An End to Cancer in 2015?

I already knew the potential of this idea was enormous.

But as I sat down and talked to these scientists, what they were saying amazed me.

“We can target DNA in a very specific way and make functional changes. We can regulate, disrupt, correct and add genes.”

What that means is we can actually take the genes out of animals, change them and put them back in.

We could create cows with no horns, sheep with more wool and cats without claws.

That all sounds great, but so what?

We’ve been able to do this in the lab for a long time.

That’s how we create special strains of mice and rats that can mimic human diseases in order to test for new drugs.

But rewriting in humans?

It’s unbelievable. Just think of the possibilities…

Already, scientists are saying that in theory, AIDS doctors could take some T-cells out of an infected person, edit their genomes and stick them back into their patient. Once they have returned to the body, each resistant cell will thrive and multiply in spite of the disease.

That means we could become immune to diseases like AIDS.

It would be the cure for what I sometimes think of as “original sin.”

I’m not talking about AIDS. I’m talking about something much broader, much bigger and much closer to home.

You see, we’re all born with defects in the very blueprints of human life that make us sicken and die. It’s written in the genomic data encoded on our DNA.

We all have errors written in the genome we inherited from our ancestors. Most of them are no more than annoying, but many of them can be deadly.

While the general content of the human genome has been mapped, each of us is as unique as a snowflake.

Until now, it’s been a dream to pinpoint and cure diseases at the cellular base.

Like a blueprint, our DNA contains the information to build other things that our cells need to function, like proteins. Some genes, influenced by environmental factors, even regulate other genes.

Our cells produce a stunning array of proteins. When a human gene holds a good blueprint, we produce a functional protein or regulatory mechanism. Unfortunately, this can fail to happen when we inherit damaged blueprints or when they aren’t copied properly when we are still made up of a few cells. If it happens when we are still a single cell, all of our future cells — which means our entire bodies — contain the same screw-up.

And new errors can introduce defects into our genome even after we’re born. This is where cancer comes from.

But what if we could rewrite that code?

What if we could rewrite all bad blueprints?

All the drugs we use right now work downstream of bad code written in the DNA by trying to fix the messes these screw-ups create.

Right now, billions are still being made treating genetic diseases the old way.

Some drugs used to treat rare genetic diseases can easily cost a $250,000 per year. And since they don’t actually modify the underlying problem, they have to be taken for life.

That’s good news for the drug companies, bad news for us.

However, by working at the DNA level itself, gene editing technology strikes at the root of human disease. Rewriting a gene to correct for an error not only repairs that cell, it repairs all future cells that come from it. It’s a permanent fix.

The possibilities for the future of humanity are enormous.

Stephen Petranek, editor of Breakthrough Technology Alert, and I have been keeping a close eye on new gene editing technology. Stephen tells us: “Gene engineering is very frustrating because in a lab environment, with a limited number of cells, gene editing is as promising as medicine gets. The problem comes in trying to get the therapy into every cell in a human body.”

But the once-impossible technology is maturing. Biotechnology companies are beginning to find ways to make gene editing in humans a practical reality — and they are producing large gains for their investors as a result.

Stephen was able to harvest a profit of 190% from one such company for his readers. In fact, the company doubled in the four months after he recommended holding shares because “the company’s approach is proving to be a huge success.”

But Stephen still recommends holding shares during a recent update to his readers on this company’s progress, because it will double again. “You can let these winnings ride with confidence,” he says.

2015 is going to be a banner year for gene editing technology. Don’t miss out on the early gains of pioneering gene editing companies.

To a bright future,

Ray Blanco
for The Daily Reckoning

The Daily Reckoning